Chronic Kidney Disease Stage 5
Conditions
Interventions
Experimental group:Hemoperfusion Regimen: PHA130 hemoperfusion cartridge is added on the basis of conventional hemodialysis.
Sponsors
Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18 - 75 years old, gender not restricted; 2. Maintenance hemodialysis treatment duration >= 3 months, stable condition; 3. Regularly undergo dialysis 3 times per week (or as per doctor's advice), Kt/V >= 1.2; 4. Voluntarily participate and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Within the past 1 month, there has been a history of acute infection, surgery, trauma or blood transfusion; 2. Complicated with severe liver dysfunction, malignant tumor or autoimmune disease; 3. Severe malnutrition or hemoglobin < 80g/L; 4. Presenting with severe cognitive impairment and unable to cooperate with the scale test (but those with extremely poor baseline test results still need to be recorded); 5. Known to be allergic to the material of the perfusion device.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Protein-bound toxins;Inflammatory/oxidative markers;Cognitive function; | — |
Secondary
| Measure | Time frame |
|---|---|
| Routine biochemistry;Blood routine test ;Coagulation function; | — |
Countries
China
Contacts
Public ContactHou Guocun
Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University
Outcome results
None listed